
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Molecular definition of cancer antigens has opened new possibilities for developing effective adjuvant melanoma immunotherapies, according to Steven A. Rosenberg, M.D., Ph.D.